Image source: Getty Images.
Sangamo reports progress that deals with hemophilia
<p class = "canvas-atom canvas text Mb (1.0em) Mb (0) – sm presented [ ] Encouraging results ] encouraged to obtain results from a clinical study of hemophilia A treatment. The data presented at a conference in Australia supported a previous announcement on preliminary recession ults which caused a 29% jump in the stock price three months ago. "data-reactid =" 30 "> Shares in Sangamo Therapeutics rose 1.1% after the gene editing specialist and partner Pfizer presented encouraging results from a clinical study of hemophilia treatment A. The data presented at a conference in Australia Supported a previous announcement of preliminary results that caused a 29% jump in the stock price three months ago.
The Phase 1/2 Dose Study is considering the SB-525, a gene therapy that corrects the defective gene that causes hemophilia. Coagulation factor VIII protein The 10 patients in the study have shown a dose-dependent increase in factor VIII levels and the therapy has been well tolerated, the new data containing results from two new patients from a cohort extension, as well as updates on positive results in the other eight
<p class = "canvas-atom canvas text Mb (1.0em) Mb (0) – -m Mt (0.8em) – sm" type = "text" content = "Pfizer takes responsibility for further development of the treatment from here, works on plans for a study leading to the FDA submittal and preparing for production of the SB-525. The two companies are also working together to use Sangamo's gene editing platform to develop treatments for amyotrophic lateral sclerosis, or Lou Gehrig's disease and frontotemporal lobar degeneration. "data-reactid =" 32 "> Pfizer will assume responsibility for the further development of the processing from here, working on plans for a study leading to the FDA submittal and preparing for the production of the SB-525.The two companies also work together to use Sangamo's gene editing platform for developing treatments for amyotrophic lateral sclerosis, or Lou Gehrig's disease and frontotemporal lobar degeneration
Non-compliance report puts CannTrust pot on hold
Canadian medical marijuana producer CannTrust was beaten with a non-compliance report from Health Canada To grow cannabis in unlicensed rooms in its largest greenhouse plant and to provide inaccurate information to the regulator Stocks decreased by 22.5%
CannTrust accepted the finding, saying that production in unlicensed rooms occurred from October 2018 to March 2019 while applications for the rooms were awaited by Health Canada, the company has put in place 5,200 kilos of dried marijuana as e produced in the unlicensed rooms and an additional 7,500 kilograms of dried cannabis equivalents on the production plant, pending quality control by Health Canada in the next 10 to 12 days.
<p class = "canvas-atom texttext Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = " CannTrust tag ] has been thrilled with the company's capacity expansion and its latest movement to the US cannabidiol market, but with the threat of a tremendous amount of cannabis – one-third more than what the company all harvested last quarter & nbsp; – potentially smoking before being sold because of seemingly poor governance, investors were wondering today if they can rely on CannTrust. "data-reactid =" 36 "> The CannTrust bulls have been thrilled with the company's capacity expansion and latest move to the US cannabidiol market. But with the threat of a tremendous amount of cannabis – a third more than what the company harvested last year – potentially goes up smoke before it is sold because of seemingly poor governance, investors today asked if they can rely on CannTrust.
<p class = "canvas-atom canvas text Mb (1.0em) Mb (0) – sm Mt (0.8em) – sm" type = "text" content = " More from Motley Fool "data-response time =" 37 "> More from Motley Fool
<p class =" canvas-atom canvas text Mb (1.0em) Mb (0)) – sm "type =" text "content =" Jim Crumly owns shares of PFE and Sangamo Therapeutics, Motley Fool recommends CannTrust Holdings, Motley Fool has a disclosure policy . "data-response time =" 45 "> Jim Crumly owns shares of PFE and Sangamo Therapeutics. Motley Fool recommends CannTrust Holdings. Motley Fool has a disclosure policy.
